Vizimpro 30 mg/1

Vizimpro 30 mg is a medication used in cancer treatment. It contains dacomitinib, a targeted therapy designed to inhibit specific proteins involved in cancer cell growth.

Vizimpro 30 mg is primarily used in the treatment of non-small cell lung cancer. It works by targeting and inhibiting the epidermal growth factor receptor (EGFR), which can help slow the growth and spread of cancer cells. This medication is often prescribed for patients with specific genetic mutations that make their cancer cells dependent on the EGFR pathway.

Common effects of Vizimpro 30 mg may include skin rashes, diarrhea, and mouth sores. Some users may also experience fatigue, loss of appetite, and changes in taste. These effects can vary in severity and may require management under medical supervision.

Vizimpro 30 mg should be handled with care. It is important to follow the prescribed dosage and administration instructions provided by a healthcare professional. Patients should be aware of potential side effects and report any severe or persistent symptoms to their doctor.

Vizimpro 30 mg may interact with certain medications, including those that affect liver enzymes. It is important to inform your healthcare provider about all medications you are taking to avoid potential interactions. Additionally, avoid grapefruit and grapefruit juice, as they can affect the metabolism of dacomitinib.